Marker Could Help Diagnose Early Pancreatic Cancer


Researchers have discovered a protein encoded by the GPC1 gene present on cancer exomes that may be used as a diagnostic tool to detect early pancreatic cancer.

Researchers have discovered a protein encoded by the glypican-1 (GPC1) gene present on cancer exomes that may be used as part of a potential noninvasive diagnostic and screening tool to detect early pancreatic cancer.

In the study, published in Nature, Raghu Kalluri, MD, PhD, chair of the department of cancer biology at the University of Texas MD Anderson Cancer Center, and colleagues isolated and observed GPC1-enriched circulating exosomes, which they called GPC1+ crExos, using flow cytometry from the blood of patients with pancreatic cancer.

The researchers found that GPC1+ crExos were present in the blood of patients with pancreatic cancer with absolute specificity and sensitivity, clearly distinguishing these patients from healthy patients or those with benign pancreatic disease.

In addition, the study showed that levels of GPC1+ crExos were significantly lower in patients after surgical resection of the tumor.

“GPC1+ crExos can be detected and isolated in blood samples that were stored in freezers almost 30 years ago, unlike circulating tumor cells (CTCs) that require large amounts of fresh blood,” said Kalluri in a prepared statement. “DNA, RNA, and proteins can be isolated from cancer exosomes isolated from stored specimen for further genetic and biological analyses. Therefore, cancer exosomes are not just a biomarker but isolating them provides a trove of cancer-specific information.”

The researchers also conducted studies in mice to determine the value of GPC1+ crExos as a screening biomarker. They found that the presence of GPC1+ crExos reliably detected pancreatic intraepithelial lesions in mice despite negative results for pancreatic disease found with MRI screening.

“Routine screening of the general population for pancreatic cancer using MRIs or CTs would be prohibitively expensive with the likelihood for many false positives,” said David Piwnica-Worms, MD, PhD, chair of the department of cancer systems imaging at MD Anderson Cancer Center, in a prepared statement. “Our study suggests the potential for GPC1+ crExos as a detection and monitoring tool for pancreatic cancer in combination with imaging, with an emphasis on its application in early detection.”

Related Videos
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content